sterna biologicals GmbH & Co. KG

sterna biologicals announces dosing of first patient in phase IIa proof-of-concept study with SB010 in moderate to severe asthma

sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS RECEIVES APPROVAL FOR INNOVATIVE PHASE II A STUDY DESIGN IN ASTHMA COMBINING A NOVEL ANTISENSE-BASED TREATMENT WITH A DIGITAL THERAPY

sterna biologicals GmbH & Co. KG raises further EUR 10.0 million (approx. USD 11.9 million) in Series A – 2nd closing private placement

Sterna biologicals secures EUR 12.0 million (approx. USD 13.0 million) in private placement

Sterna biologicals to attend international partnering and investor conferences in November

sterna biologicals invited to present at the Goodwin – Solebury Trout – NASDAQ European Biotech Investor Day 2019

sterna biologicals strengthens management team to progress towards phase IIb development.

Sterna Biologicals holds Scientific Advisory Board meeting at 14th Congress of ECCO to advance phase IIb clinical development program of SB012 in Ulcerative Colitis

Sterna Biologicals holds Scientific Advisory Board meetings to advance phase IIb clinical development program of SB010 in asthma

Sterna biologicals prepares for phase IIb clinical program with GATA-3 antagonist drug candidates SB010 in asthma and SB012 in ulcerative colitis

STERNA BIOLOGICALS TO ATTEND BIO-EUROPE(R) 2018 24th ANNUAL INTERNATIONAL PARTNERING CONFERENCE

Successful device feasibility study with sterna biological’s asthma drug candidate SB010 enable selection of optimal nebulizers for late-stage development and commercialization

STERNA BIOLOGICALS PRESENTS DETAILED RESULTS FROM SUCCESSFUL PHASE 2a STUDY WITH GATA-3 SPECIFIC DNAZyme FORMULATION SB012 IN PATIENTS WITH ULCERATIVE COLITIS

STERNA BIOLOGICALS ANNOUNCES DATA WITH GATA-3 SPECIFIC DNAZYME SB012 TO BE PRESENTED AT DIGESTIVE DISEASE WEEK(R)

STERNA BIOLOGICALS ANNOUNCES PHASE IIA DATA WITH SB010 PUBLISHED IN RESPIRATORY RESEARCH

sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS ZEIGT PHASE-2a-STUDIENDATEN ZUR SICHERHEIT UND WIRKSAMKEIT DER GATA-3 SPEZIFISCHEN DNAzyme-FORMULIERUNG SB012 IN PATIENTEN MIT COLITIS ULCEROSA

sterna biologicals GmbH & Co. KG: STERNA BIOLOGICALS REPORTS PHASE 2a STUDY DATA DEMONSTRATING EFFICACY OF ITS GATA-3 SPECIFIC DNAZyme FORMULATION SB012 IN PATIENTS WITH ULCERATIVE COLITIS

STERNA BIOLOGICALS TO PARTICIPATE IN UPCOMING INTERNATIONAL CONFERENCES IN H1 2018

STERNA BIOLOGICALS APPOINTS CHRISTIAN PANGRATZ AS CHIEF EXECUTIVE OFFICER